Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc TARA

Healthcare Biotechnology
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is... see more

Recent & Breaking News (NDAQ:TARA)

Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

GlobeNewswire August 5, 2021

Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

GlobeNewswire July 7, 2021

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

GlobeNewswire June 10, 2021

Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire May 13, 2021

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

GlobeNewswire May 6, 2021

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

GlobeNewswire April 23, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 19, 2021

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

GlobeNewswire April 19, 2021

Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview

GlobeNewswire March 11, 2021

Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference

GlobeNewswire March 10, 2021

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

GlobeNewswire February 4, 2021

Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

GlobeNewswire February 2, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2021

Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer

GlobeNewswire December 7, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2020

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

GlobeNewswire November 24, 2020

Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview

GlobeNewswire November 12, 2020

Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 11, 2020

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2020